# Newly Diagnosed Glioblastoma

> **NCT04959500** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 150 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Anlotinib Hydrochloride
- **DRUG:** Placebo
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04959500
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-21
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04959500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04959500, "Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04959500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*